&w=3840&q=100)
Obesity injections may have less weight loss effect in reality: Study
Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar.
The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting.
"Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said.
"According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomised clinical trial settings," Dr Gasoyan said.
The researchers examined 7,881 adult patients with an average body mass index (BMI) of over 39 -- classified as 'severe obesity'. Of these, 1,320 had pre-diabetes at the start of the study, which meant they were at a higher risk of developing type 2 diabetes.
The participants were started on obesity treatments between 2021 and 2023 with semaglutide or tirzepatide injectables.
Following up on the participants a year after starting with the treatment, the average weight loss among those who discontinued injections within three months was 3.6 per cent, compared to 6.8 per cent in those who discontinued within 3-12 months.
"Mean percentage weight reduction at one year was 8.7 per cent, and it was 3.6 per cent with early discontinuation (three months), 6.8 per cent with late discontinuation (3-12 months) and 11.9 per cent with no discontinuation," the authors wrote.
Furthermore, those on a high-maintenance dosage -- the amount required to sustain the effects of the medication -- lost 13.7 per cent of their body weight with semaglutide and 18 per cent with tirzepatide, the researchers said.
Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment.
"The average weight reduction in this cohort was lower than that observed in the main phase 3 (clinical) trials, likely because of higher rates of discontinuation and lower maintenance dosages," the team wrote.
They identified that those not discontinuing medications or taking a high-maintenance dose were among the factors related to more chances of losing at least 10 per cent of one's body weight in a year.
Overall, over a fifth of the study group was found to have discontinued their medications within three months of the study's start, while 32 per cent discontinued within 3-12 months.
Reasons for discontinuing treatment included costs and insurance-related issues, side effects and medication shortages, the researchers said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
an hour ago
- Indian Express
Eli Lilly's weight loss drug most effective at preventing heart attacks and strokes: What new study means for Mounjaro users
US pharmaceutical giant Eli Lilly's weight-loss drug tirzepatide was found to be more effective in preventing heart attacks and strokes compared to its previous GLP-1 medication dulaglutide. The preliminary results from a yet-to-be published large trial showed that the risk of a major adverse cardiovascular event was eight per cent lower in people who were put on the new therapy. Tirzepatide is sold under the brand name Mounjaro. Belonging to a group of medicines called incretin mimetics — which mimic hormones that play a key role in regulating insulin levels, blood sugar levels and appetite — both the medicines were initially approved for the treatment of diabetes, with tirzepatide later receiving approval for the treatment of obesity and other related conditions such as obstructive sleep apnea. Dulaglutide mimics the action of the GLP1 hormone while tirzepatide mimics the combined action of GLP1 and GIP hormones. The trial found an eight per cent lower risk of major adverse cardiovascular events such as cardiovascular deaths, heart attacks and strokes in people who were on tirzepatide as compared to those on dulaglutide. Tirzepatide was found to reduce the risk of such events by 28 per cent against a placebo, by comparing the results of the current trial with a 2019 trial of dulaglutide against placebo. Another important finding of the trial was a 16 per cent lower risk of all-cause mortality in people who were on tirzepatide, compared to those on dulaglutide. The company said that the medicine reduced the risk of all-cause mortality by 39 per cent against placebo — again by comparing data from the current trial with the 2019 dulaglutide trial. The current trial also demonstrated that tirzepatide was better at slowing the decline of kidney function in participants who were at a high risk of chronic kidney disease. Tirzepatide slowed the decline in the kidney's filtration rate by 3.54 mL/min/1.73 m2 as compared to dulaglutide. The trial also showed that tirzepatide was more effective at reducing three-month average blood glucose levels as well as weight when compared to dulaglutide. The use of tirzepatide led to a 1.73 per cent reduction in HbA1c levels at 36 months as compared to 0.9 per cent with dulaglutide use. The participants on tirzepatide dropped 12 per cent of their body weight during the trial period as compared to 4.95 per cent with dulaglutide. With the new generation weight-loss drugs gaining popularity across the globe, it is essential for these drugs to demonstrate protection against heart diseases, especially since it is a common comorbidity along with obesity and diabetes. While there is a link between uncontrolled blood glucose levels and heart disease, not all diabetes medicines protect the heart. In fact, a previous class of diabetes medicines called glitazones were found to increase the risk of heart failure. With the end-game of these medicines being saving lives — and not just controlling blood glucose levels or body weight — the US Food and Drug Administration now requires the medicines to demonstrate that they do not harm the heart or, better yet, they offer protection against cardiovascular events. The new classes of diabetes medicines such as GLP-1 and SGLT-2 were found to protect the heart as well. Importantly, the competitor of Eli Lilly's tirzepatide — Novo Nordisk's semaglutide — has FDA approval as treatment for reducing risk of heart diseases. These medicines work by improving the secretion of insulin, which helps in removing glucose from the blood to the cells for use as energy. They inhibit the secretion of the hormone glucagon that stimulates the liver to release stored glucose into the bloodstream, slow down the emptying of the stomach so that the blood glucose levels do not spike suddenly and reduce appetite by signalling to the brain that you are full. The drugs have become popular owing to their weight-loss properties, which at times can be as effective as bariatric surgery. Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
Time of India
2 hours ago
- Time of India
Fake medication is a problem across the world Matthew Ward Agius
Representative image Amid rising demand for popular medications, experts and industry groups are concerned regulators may not be able to keep pace with the speed of counterfeiters. "A doctor simply writes down the prescription. They don't care where the patient buys the drug," said Saifuddin Ahmed, a public health practitioner and epidemiologist at Johns Hopkins University in the US. "It is critically important that a health care provider should be engaged. The [regulators are] not enough," Ahmed told DW. Nowhere else is the challenge more obvious than with the huge demand for products like Wegovy and Zepbound. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like What Happens When You Massage Baking Soda Into Your Scalp Read More Undo They contain active compounds called semaglutide or tirzepatide, which were originally designed to treat type 2 diabetes. But these drugs were found to have a side effect that triggered substantial, sustained weight loss. Demand rose from people wanting to lose weight, and that caused a shortage. Fakes have filled the gap. Fake drugs are a global problem Drug counterfeiting is a major global problem . The World Health Organisation (WHO) estimates that one in 10 pharmaceuticals are fakes that carry no guarantee of any health benefits. While this is mainly a problem in low-and-middle income countries, especially parts of Africa and Asia, around 1% of people in high-income nations also obtain medication from unregulated sources. In some cases, these drugs may have no effect. In other cases, however, ingredients in the fake medication may lead to adverse reactions or create new health problems. "Purchasing medicine online from unregulated, unlicensed sources can expose patients to potentially unsafe products that have not undergone appropriate evaluation or approval, or do not meet quality standards," said the US regulator, the Food and Drug Administration (FDA) in 2023, when it issued its first warnings about the problem. In 2024, the WHO issued a global warning that batches of fake Ozempic were flooding the black market. More recently, in July 2025, data from the UK National Pharmacy Association found one in five Britons had attempted to obtain weight loss treatments in the previous year. It warned that the high demand for these medicines carried the risk that people would "resort to unregulated online suppliers instead of regulated pharmacies." Where are people buying counterfeit medicine? Unregulated pharmaceuticals are being sold via online-only pharmacies, international drug shopping and organised criminal distributors. These digital marketplaces are not online stores for established pharmacies, but sites that seemingly offer medicine at a fraction of the usual cost. The drugs may look identical to genuine medicines online, but when delivered often have spelling errors on the packet or incorrect ingredient listings. But it's not only fake drugs or placebos. Regulators have raised concern about compounding, where medicines that have been approved individually can be formulated to produce non-regulated "compounds" for individual patients. In some regions of the world, including the US, trained pharmacists are allowed to compound medicines, but even then, the practice is less regulated than the stringent approvals that drug manufacturers must meet to bring their products to market. For example, when the FDA temporarily allowed the compounding of weight loss drugs to address a product shortage, some pharmacists used semaglutide salts — which are not approved by regulators — instead of semaglutide itself. This led to reports of side effects. And it wasn't just trained compounding pharmacies that were formulating these products in the US. Ahmed said, "this is done in [places] like gymnasiums and spas." The FDA has now stopped allowing compounded versions of these weight loss drugs, but it is concerned that unregulated online pharmacies are still making substandard products available. Raising awareness about fake drugs To address concerns that consumers may seek unsafe products from unregulated sources, the FDA operates a campaign called BeSafeRx that provides guidance for consumers to identify genuine pharmaceuticals. In the European Union, safety features on medicines are mandated, and include standardized labeling practices. In a statement provided to DW, the European Medicines Agency said "patients should only use online retailers registered with the national competent authorities in the EU Member States, to reduce the risk of buying substandard or falsified medicines." Europol, which is responsible for law enforcement for pharmaceutical crime across member states, has coordinated regular actions across the bloc in collaboration with US and Colombian partners. In a 2023 operation, more than 1,284 people were charged for offenses related to the trafficking of counterfeit and misused medicines and doping substances. As well as local awareness campaigns and enforcement initiatives, the key measure, Ahmed said, was to help improve awareness between patients and their health practitioners. Ahmed heads the Johns Hopkins University's BESAFE initiative, which investigates risks and interventions to prevent the uptake of substandard and counterfeit medication. Surveys undertaken by BESAFE have found that within the US and South Africa, awareness of where to safely buy prescriptions and report fakes or adverse events is low. He said building trust between consumers, medical practitioners and regulators may help avoid the risks of counterfeit and unregulated drug purchases.
Hindustan Times
8 hours ago
- Hindustan Times
Gastroenterologist says ‘chewing sugar-free gum after meals, sleeping on left' reduces heartburn; 7 natural remedies
A painful, burning feeling or discomfort in the middle of your chest, possibly involving the neck and throat, that may worsen when lying down, is known as heartburn. According to the Cleveland Clinic, it is caused by stomach acid rising into your oesophagus (reflux), which runs through your chest, close to your heart. Chewing sugar-free gum after eating increases saliva production, which helps neutralise and wash away acid. (Freepik) Also Read | Cardiologist says 'ECG only gives 30% information about condition of your heart'; shares 2 powerful tests you must do 7 natural heartburn remedies While people often resort to medications to cure themselves of heartburn, did you know there are a few natural heartburn remedies, too, that you can practice at home? In a post shared on July 30, Dr Joseph Salhab, a gastroenterologist based in the US, shared 7 natural heartburn remedies. He also backed the tips with science by citing studies. Let's find out: 1. Chewing gum after meals clears acid Chewing sugar-free gum after eating increases saliva production, which helps neutralise and wash away acid that has crept up into the oesophagus. The same was researched by experts in a November 2005 study - 'The effect of chewing sugar-free gum on gastro-esophageal reflux' - shared on PubMed. 2. Walking after meals reduces reflux Citing a March 2025 study, the gastroenterologist said, 'Taking a light walk after eating helps to significantly reduce reflux episodes and has even been shown in clinical trials to improve the effectiveness of acid-reducing medications.' 3. Belly breathing stops acid from rising Practising diaphragmatic (belly) breathing can strengthen the muscular valve between the stomach and oesophagus, improving its ability to prevent acid from coming back up. He backed the claim with a 2011 study: Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomised, controlled study. 4. Papaya has enzymes to fight reflux 'Beyond basic nutrition, papaya acts as a 'functional food' thanks to its unique enzymes. The star enzyme, papain, is well-known for its ability to help break down proteins, which can ease symptoms of indigestion and support overall digestive wellness,' Dr Salhab said. 5. Sleeping on your left side helps at night Per an October 2023 study, he stated, 'Due to the shape and position of the stomach, sleeping on your left side keeps the junction between the stomach and oesophagus above the level of stomach acid, reducing nocturnal reflux.' 6. Vaping and alcohol cause ulcers Per the gastroenterologist, both alcohol and the chemicals in e-cigarettes can relax the lower oesophageal sphincter, the critical barrier that keeps stomach acid where it belongs, leading to increased reflux. 7. Weight loss can cure acid reflux 'For those who are overweight, losing excess body weight can significantly reduce or even completely resolve symptoms of acid reflux by decreasing abdominal pressure on the stomach,' he said. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
